INTRODUCTION
Patients with diabetes mellitus may develop an acute severe illness that necessitates a level of care that can only be provided within an intensive care unit (ICU) [1] . In the majority of critically ill patients with pre-existing diabetes, the pathophysiological response to the acute illness or injury, and/or the treatments involved, may lead to deterioration in glycaemic control. Despite the high and increasing prevalence of diabetes (both within the community and in the critically ill), the optimal management of glycaemia in critically ill patients with pre-existing diabetes remains unknown. However, recent data has highlighted the therapeutic uncertainties specific to these patients.
The majority of critically ill patients with diabetes have type 2 diabetes [2] . The limited information relating to patients with type 1 diabetes precludes speculation as to whether management of glycaemia in this group should be different from that in type 2 diabetes. Accordingly, this review focuses on critically ill patients with type 2 diabetes addressing issues including prevalence, potential rationale for harm and evidence for personalised therapy.
PREVALENCE
In the community type 2 diabetes occurs frequently with global health expenditure estimated at US $376 billion in 2010, which is expected to rise to US $490 billion by 2030 due to increasing prevalence [3, 4] . In Australia it is estimated over the last 15 years, the prevalence has increased from 8.5% to 12.0% [5] .
There is a substantial variation in the prevalence of diabetes between countries, peaking in Nauru (31%) [6] . Factors relating to the increase in prevalence include increasing obesity, increasing age and racial region. A limitation in estimating prevalence is that many patients remain unaware of their diagnosis.
For example, the estimated prevalence in the United States is 13% of the population, of which 40% is unrecognised or undiagnosed [7] .
Diagnosis of diabetes
The prevalence of recognised and unrecognised diabetes varies according to the definitions used, as well as the location and the populations studied. The current diagnostic criteria used by the American Diabetes Association (ADA) involves one of the following; an HbA1c ≥ 6.5, a fasting glucose ≥ 7 mmol/L, a 2 h post glucose tolerance test following a 75 g oral glucose load of ≥ 11.1 mmol/L, or a random blood glucose ≥ 11.1 mmol/L with symptoms of hyperglycaemia [8] . These criteria were ratified by the World Health Organization (WHO) in 2011 [9] . Given each test (HbA1c, fasting, postprandial or random blood glucose) reflects different physiological phenomena, different populations may be diagnosed when using each criterion [10, 11] . Each diagnostic test has advantages and disadvantages. Both the fasting glucose and 2 h post glucose tolerance test are established standards, relatively rapid and easy to perform, and predict microvascular complications. However, these tests are subject to day-to-day variability, require patients to fast and only reflect glucose homeostasis at a single point in time [12] . HbA1c is convenient (with no fasting required), can predict microvascular complications, is a better predictor of macrovascular disease (than fasting glucose or 2 h post glucose tolerance test) and has low day-today variability [8, 12] . Additionally, as the physiological responses to acute illness cause deterioration in glycaemia, estimating glucose control prior to the acute illness -using markers such as HbA1c -to accurately determine which patients have unrecognised diabetes and which patients have "stress hyperglycaemia" is possible [13] . Weaknesses include variations amongst ethnic groups and age, it may be misrepresentative in certain medical conditions (such as certain forms of anaemia and haemoglobinopathies) and the need for a validated, standardised assay [12] .
Prevalence of diabetes in hospitalised patients
Compared to the general population, the prevalence of diabetes in hospitalised adult patients (i.e., admitted to general wards) is considered to be greater. Depending on the population, estimates range from between 11%-35% of all patients (Table 1) .
Numerous studies in the critically ill have evaluated the prevalence of glucose intolerance (Table 1) . However, a limitation of the studies reported is that investigators were unable to identify those patients who had so-called "stress hyperglycaemia" (or critical illness associated hyperglycaemia (CIAH) -the condition of acute glucose intolerance that is confined to the period of critical illness) and those who have unrecognised diabetes. Several studies use either fasting blood glucose (≥ 7 mmol/L) and/or random Kar P et al . Managing ICU patients with type 2 diabetes glucose concentrations (≥ 11.1 mmol/L) for diagnosis of diabetes [14] [15] [16] .
Investigators have also measured glycated haemoglobin (HbA1c) on admission to identify hospitalised patients with unrecognised diabetes. A prospective observational study of 695 patients in Boston, Massachusetts [17] , selected a cutoff HbA1c of > 6.5% to diagnose diabetes, with 19% of patients having diabetes previously diagnosed and 5% having undiagnosed diabetes. Another study of 971 patients admitted to the general medical ward of an urban hospital located in the Bronx, New York [18] -which may be assumed to admit a larger cohort of lower-income patients -35% were known to have diabetes, and 16% undiagnosed diabetes, using an HbA1c ≥ 6.5.
In summary, the prevalence of diabetes in hospitalised patients varies according to geography. In the developed world, diabetes is more prevalent amongst lower socioeconomic groups [19] [20] [21] . Furthermore, diabetes is a risk factor for certain diseases (e.g., cardiovascular disease) and prevalence will be greater if a specific population (e.g., patients presenting with myocardial ischaemia) is studied [22] .
Prevalence of diabetes in patients admitted to ICU
The prevalence of diabetes in patients admitted to the ICU is estimated to be between 12%-40% (Table  2) . Similar to the prevalence in hospitalised patients, the wide range reflects the definitions used and the population studied. Multiple single centre observational studies from the United States [23] [24] [25] report prevalence between 13% and 21%, therefore it is likely that the true prevalence is close to this range. More recently, Falciglia et al [26] undertook a retrospective cohort study across 173 ICUs in the United States and reported that 30% of the 259040 patients had a history of diabetes according to ICD-9 codes [26] . A single centre, observational study from London, United Kingdom [27] , found 16% of patients had a history of diabetes. A retrospective observational study of 4946 patients admitted to one of two hospitals in Melbourne and Sydney, Australia [28] , reported 15% had diabetes. While a single, mixed medical/surgical ICU from Amsterdam, The Netherlands [29] , found 12% of 5961 patients admitted had a history of diabetes. These data indicate that the prevalence in other developed countries may be similar to, or slightly less than, the United States.
Data from international studies are consistent with this concept. Stegenga et al [30] utilised data collected as part of a randomised interventional study [31] to evaluate whether diabetes affects the outcome of sepsis in patients admitted to one of 164 ICUs across 11 countries and reported that 23% had pre-existing diabetes. In retrospective observational data derived from 44964 patients admitted to one of 23 ICUs worldwide [32] , 29% had a history of diabetes documented in their medical records, but the prevalence varied substantially according to geography. For example, in an ICU from Geelong, Australia, the prevalence was 14%, while in a hospital < 100 km away (Melbourne) it was 24%, whereas patients admitted to Tampa Bay, United States, the prevalence was 39%.
The prevalence of diabetes in the critically ill varies across studies. Multiple observational studies estimate the prevalence at 12%-30% [23] [24] [25] [26] [27] [28] [29] 30, [32] [33] [34] [35] . However, these studies have significant limitations. Most importantly, the prevalence may be under represented due to diabetes that is either unrecognised or not documented.
A number of interventional studies have also reported diabetes prevalence in ICU patients (Table  2) . Two prospective, randomised, controlled studies of surgical and medical ICU patients admitted into the ICU in Leuven, Belgium, compared an intensive insulin therapy (ITT, blood glucose level 4.4-6.1 mmol/L) vs conventional treatment (insulin started if the blood glucose was > 12 mmol/L and maintained between 10-11.1 mmol/L) [36, 37] . These studies reported diabetes at 13% and 17% respectively.
Other interventional studies include single centre [38, 39] and multicentre trials [40] [41] [42] , with the largest being in 2009, the NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation) study. This was conducted across 42 ICUs body of evidence suggests, chronic glucose control may have implications on optimal acute glucose ranges in the critically ill. Hospital and ICU prevalence of unrecognised diabetes can be estimated from the studies mentioned (Tables 1 and 2 ) along with other studies cited below (Table 3 ). Hospital prevalence is estimated to be between 5%-16% [16] [17] [18] 43] and ICU prevalence between 6%-14% [34, 44] . The prevalence in patients with ischaemic heart disease (e.g., presenting with acute myocardial infarction) appears to be higher [45, 46] . In two European studies, patients with an acute myocardial infarct and without a history of diabetes subsequently underwent an oral glucose tolerance test (OGTT) to diagnose diabetes [45, 46] . The prevalence of diabetes was found to be over 30% at discharge, and between 25%-31% at 3 mo. In London (United Kingdom), Emergency Department patients were throughout Australia, New Zealand and Canada [41] , and noted 20% of its 6029 patients with a history of diabetes, with the majority (92%) having type 2 diabetes.
It should be recognised that there are limitations to using data from these interventional studies. Inclusion into these studies usually requires hyperglycaemia and therefore leads to selection bias, which artificially increases any estimate of prevalence. The interventional trials estimated ICU prevalence at 13%-40% [36] [37] [38] [39] [40] [41] [42] .
Prevalence of unrecognised diabetes
Patients may have diabetes that is unrecognised prior to admission [2] . This may not represent "stress hyperglycaemia" or CIAH -as the hyperglycaemia is chronic rather than acute. Unrecognised diabetes is important as it not only impacts on estimations for the actual prevalence of the condition, but, as a growing
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Hospital records N/A Treggiari et al [25] 2008 Kar P et al . Managing ICU patients with type 2 diabetes screened for diabetes via fasting blood glucose [47] and it was reported that 3% patients had unrecognised diabetes.
We recently performed a single centre observational study in a mixed medical/surgical ICU in Adelaide, Australia, and separated patients with diabetes (either known or unrecognised) and CIAH using HbA1c to accurately estimate the prevalence of each condition [34] . Of 1000 consecutively admitted ICU patients, 22% had known diabetes (5% were type 1) and 6% had unrecognised diabetes (HbA1c ≥ 6.5%). The absence of previously diagnosed diabetes was confirmed by a phone call to the patient's usual local medical officer (general practitioner).
Subsequently, Hoang et al [44] also estimated the prevalence of undiagnosed diabetes in a prospective, observational study in a single medical ICU [44] . All patients with hyperglycaemia and those with known diabetes underwent measurement of HbA1c with diabetes defined as an HbA1c ≥ 6.5%. Sixty-six percent of the 299 patients enrolled into the study had a history of diabetes. Of the remaining 102 hyperglycaemic patients without diabetes, 14% had an HbA1c ≥ 6.5%.
In summary the prevalence of undiagnosed diabetes is difficult to determine, and as previously noted, depends on the definitions used and the location of the patient population. Current "best estimate", albeit on limited data from single centres, suggest that the prevalence of undiagnosed diabetes is either similar to, or slightly greater than, the background prevalence in the community.
RATIONALE FOR HARM FROM

HYPERGLYCAEMIA, HYPOGLYCAEMIA AND GLYCAEMIC VARIABILITY
Hyperglycaemia
Hyperglycaemia in type 2 diabetes reflects the outcome of factors affecting both insulin secretion, with β-cell dysfunction resulting in a relative insulin deficiency, and insulin resistance as a result of both environmental and genetic factors [48, 49] . However, the pathogenesis of hyperglycaemia in the critically ill patient, either with CIAH, or in those with pre-existing diabetes and experiencing a deterioration in their glucose control, is complex and poorly understood [2] . Patient predisposition (including insulin resistance and β-cell function), the underlying illness (which can result in catecholamine release, stimulation of the hypothalamic-pituitary-adrenal (HPA) axis, and the release of inflammatory cytokines) and the management involved (including glucocorticoids, vasopressors and nutrition) appear to be of major relevance [1] . The activation of the HPA axis and the sympathetic system cause the "stress" response. In the majority of patients "stress" hormones (including cortisol and catecholamines) markedly increase. In addition, the underlying illness may stimulate the production of cytokines (such as TNF-α, IL-1 and IL-6) [1, 50] . These three components (HPA axis, sympathetic system and cytokine release) lead to excessive gluconeogenesis, glycogenolysis and insulin resistance, thereby augmenting stress hyperglycaemia [50] . Glucagon is the major modulator of gluconeogenesis and may be stimulated by TNF-α, however cortisol and adrenaline (epinephrine) are also likely to contribute [1, 51, 52] . Insulin resistance is thought to occur due to a number of pathways. Glucose enters cells via plasma membrane glucose transporters (GLUTs), which are down regulated in times of stress, possibly due to the presence of TNF-α and IL-1 [50] . Diminished glucose uptake by peripheral tissue may occur due to high cortisol and adrenaline (epinephrine) concentrations [1, 53] . As discussed, acute illness results in increased level of cytokines, which exacerbates hyperglycaemia and stimulates inflammation and oxidative stress [1] . It should be considered that acute hyperglycaemia may represent a "protective" physiological response of Norhammer et al [45] 2002 OGTT 51 (31%) at discharge 36 (25%) at 3 mo 164 144
Multicentre (Sweden) Post AMI, Hospital/ICU George et al [47] 2005 Fasting blood glucose ≥ 7 mmol/L 13 (3%) 427 London, United Kingdom Emergency Department
Wexler et al [17] 2008 HbA1c > 6.5 33 (5%) 695 Boston, United States Hospital Lankisch et al [46] 2008 OGTT 31 (32%) at discharge 19 (31%) at 3 mo 96 62
Wuppertal, Germany Post AMI, Hospital/ICU Mazurek et al [18] 2010 HbA1c ≥ 6.5 152 (16%) 971 New York, United States Hospital Feldman-Billard et al [16] 2013 Fasting blood glucose
Plummer et al [34] 2014 HbA1c ≥ 6.5 55 (6%) 1000 Adelaide, Australia ICU Hoang et al [44] 2014
HbA1c ≥ 6.5 14 (14%) 102 New Haven, United States Medical ICU Ochoa et al [43] the host during periods of stress [50] . An acute rise in glycaemia may facilitate glucose delivery at critical times and promote anti-apoptotic pathways, protecting against cell death [50] . While uncontrolled acute hyperglycaemia is clearly harmful, the threshold at which harm occurs in the critically ill patient remains to be determined [2] . The majority of studies that have evaluated this issue have enrolled heterogenous cohorts -and patients with diabetes only comprised a small proportion of the sample evaluated. Based on recent data it is increasingly likely that the glucose threshold in a patient with diabetes, particularly those with chronic hyperglycaemia, will differ from that in a patient who is naïve to hyperglycaemia. A patient with poorly controlled diabetes, i.e., with a history of high blood glucose levels and consequently high HbA1c, will be more tolerant of hyperglycaemia but susceptible to the adverse effects of hypoglycaemia (see below), such that the thresholds for both variables are greater than a patient who is naïve to hyperglycaemia -either those with well controlled diabetes or those with CIAH.
Multiple studies have examined the effects of hyperglycaemia on morbidity and mortality in the ICU population with inconsistent and controversial outcomes. Moreover, the majority of these studies have not categorised patients into those with chronic hyperglycaemia or acute glucose intolerance.
There are numerous observational studies (Table 4) . In 2005, a case controlled study of 7285 ICU patients reported that in individuals without known diabetes, mortality was increased when blood glucose levels were > 8 mmol/L but this signal was absent in patients with diabetes [35] . Overall, mortality was significantly greater in patients without diabetes when compared to patients with diabetes. A retrospective study of 2713 patients admitted into ICU [23] reported an association between mortality and hyperglycaemia in patients without a history of diabetes in the cardiac, cardiothoracic, and neurosurgical intensive care units. In an audit of 5365 ICU 
Overall message
Rady et al [35] Egi et al [28] Falciglia et al [26] 2009 259040 Glycaemia vs mortality 5-fold inc in mortality from lowest mean blood glucose, 3.9-6.1 mmol/L (8%) to highest, > 16.7 mmol/L (41%) 2-fold inc in mortality from lowest mean blood glucose, 3.9-6.1 mmol/L (6%) to highest, > 16.7 mmol/L (11%) Hyperglycaemia associated with inc mortality in diabetics and non diabetics Mortality greater for hyperglycemic non diabetics patients Stegenga et al [30] 2010 830 DM vs outcomes of sepsis Admission hyperglycaemia (> 11.1 mmol/L) associated with inc 28 and 90 d mortality (P < 0.03) Admission hyperglycaemia had no effect on diabetic mortaltity Diabetes did not influence mortality in sepsis Krinsley et al [32] Kar P et al . Managing ICU patients with type 2 diabetes patients evaluated before and after implementation of an intensive glucose control policy [24] , mortality was increased in patients with hyperglycaemia who were not known to have diabetes when compared to those with diabetes. In 2008, Egi et al [28] reported a retrospective study of 4946 patients in which ICU mortality increased with increasing mean blood glucose level in patients without diabetes but this signal of harm was absent in those with pre-existing diabetes [28] . A retrospective cohort study of 259040 ICU admissions also reported an association between mortality and hyperglycaemia, with the relationship far stronger in patients without a diagnosis of diabetes when compared to those with pre-existing diabetes [26] . A retrospective analysis of a previous study [31] included 830 patients admitted with severe sepsis (defined as sepsis associated with acute organ dysfunction) [30] , and reported that hyperglycaemia was predictive of subsequent death in those patients not known to have diabetes. Additionally, a multicentre retrospective study of 44964 patients divided into 2 cohorts (with and without known diabetes) [32] , reported increased mortality with higher mean blood glucose concentrations (≥ 7.8 mmol/L) when compared to blood glucose concentrations 4.4-7.8 mmol/L in patients without diabetes. In contrast, patients with diabetes were more likely to die when mean blood glucose concentrations were between 4.4-6.1 mmol/L when compared to patients with greater blood glucose concentrations (6.2-10 mmol/L). A number of interventional studies have evaluated the relationship between chronic and acute hyperglycaemia and outcomes (Table 5) . In a pooled analysis of studies conducted in a single centre in Leuven, intensive insulin therapy (ITT, aiming for blood glucose concentrations between 4.4-6.1 mmol/L) was reported to reduce mortality and morbidity in patients without a diagnosis of diabetes, but this was not the case in patients with diabetes, if anything, there was a trend for harm with intensive insulin therapy in patients with diabetes such that mortality was nonsignificantly greater at a lower mean blood glucose range (6.1-8.3 mmol/L, 21.2% vs < 6.1 mmol/L, 26.2%, P = 0.4 and > 8.3 mmol/L, 21.6%, P = 0.9) [54] . Subsequently, a number of interventional, randomised, controlled trials, containing patients with diabetes, comparing ITT to more conventional glucose targets have been published [38] [39] [40] [41] [42] . A trial of 523 mixed (medical and surgical) ICU patients [39] reported no survival benefit in patients with diabetes with ITT, but ITT was associated with an increased prevalence of hypoglycaemia. The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study assigned 537 ICU patients with severe sepsis to either ITT or more conventional glucose targets while receiving either 10% pentastarch or a modified Ringers lactate in a two-by-two factorial study [38] . The study was suspended at interim analysis for safety reasons with ITT being associated with increases in episodes of severe hypoglycaemia and adverse events. De La Rosa et al [42] also evaluated ITT in 504 ICU patients (61 with diabetes) and there was no mortality or morbidity benefit observed, but an associated increased risk of hypoglycaemia, when administering ITT. In 2009, the NICE-SUGAR study compared ITT with conventional glucose control in 6029 ICU patients and established that the observations from the initial Leuven studies regarding ITT were not generalisable outside that specialised institution [41] . However, amongst the 1211 patients with pre-existing diabetes in the NICE-SUGAR study the administration of ITT did not appear more harmful than in patients without diabetes. The Glucontrol study [40] , an international, multicentre trial involving over 1000 ICU patients was stopped early due to protocol violations, and it was, accordingly, underpowered. However, there was no evidence to suggest any benefit with ITT and data in patients with diabetes were not specifically described.
Recently a number of studies have attempted to measure chronic glycaemia as a dynamic (HbA1c), rather than a binary, variable (i.e., presence of diabetes -yes/no) ( Table 6 ). Egi et al [55] performed a retrospective observational study of 415 patients with diabetes (from two Australian ICUs) in whom glycated haemoglobin (HbA1c) had been measured within 3 mo of their critical illness and evaluated how this measure of pre-existing glycaemia impacted on the interaction between acute glycaemia and mortality [55] . It was reported that in patients with elevated preadmission HbA1c levels (> 7%) the number of deaths were significantly fewer when blood glucose concentrations were > 10 mmol/L. Consistent with this observation, we recently measured HbA1c on admission and glucose concentrations for the first 48 h of ICU admission [34] and observed that acute peak glucose concentrations were associated with increased mortality only in patients with adequate premorbid glycaemic control (defined as HbA1c < 7%), but not in patients with chronic hyperglycaemia (defined as an HbA1c ≥ 7%). This finding was also supported by Hoang et al [44] who assessed the prevalence of undiagnosed diabetes (i.e., HbA1c ≥ 6.5%) among those with hyperglycaemia in a medical ICU. Patients with an HbA1c ≥ 6.5% were found to have significantly lower mortality compared to those with an HbA1c < 6.5% (11.7% vs 19.3%, P = 0.038), despite having greater glucose concentrations. In summary the outcomes of the largest and most generalisable randomised study are consistent with the concept that the optimal glucose concentrations in unselected critically ill patients are between 6-10 mmol/L [41] . However, observational data, post-hoc analysis of interventional studies and studies measuring chronic glycaemia as a dynamic variable suggest that patients with pre-existing diabetes may warrant higher targets. Indeed, there is increasing data suggesting that targets should be personalised depending on both 
Hypoglycaemia
In most cases, treatment of hyperglycaemia in the critically ill involves the use of insulin, which is associated with increased risks of both hypoglycaemia and glycaemic variability [56] . The severity of illness may also result in a hypoglycaemia and therefore it is important to be circumspect when attributing mortality to hypoglycaemia [57] .
Additionally, hypoglycaemia may have adverse biological effects including an increase in systemic inflammatory response, impairment of the sympathetic nervous system, inhibition of the biological response to stress, along with cerebral vasodilation and neural damage [2, 58] . Experimentally, the use of insulin and consequent hypoglycaemia may be associated with hypotension, vasodilation, and reduced autonomic responses to subsequent hypoglycaemic episodes [58] . Furthermore, critically ill patients may be more prone to the effects of hypoglycaemia itself, which may include cardiac arrest, seizure and coma [59] .
Studies examining the effects of hypoglycaemia in critically ill patients with pre-existing diabetes are limited. Interventional studies describing this relationship have been summarised (Table 6) . Of note, post hoc analysis of the NICE-SUGAR data indicate that intensive insulin therapy increases episodes of moderate (2.3-3.9 mmol/L) and severe (≤ 2.2 mmol/L) hypoglycaemia, both of which are associated with increased risk of death [56] . This relationship was similar among patients with and without a diagnosis of diabetes. In addition to these studies, there are a number of observational studies that have evaluated this association ( Table 7) . A retrospective database review of 408 ICU patients (102 index cases, 306 controls) published in 2007 [60] reported that a history of diabetes was associated with severe hypoglycaemia and that a single 700 June 10, 2015|Volume 6|Issue 5| WJD|www.wjgnet.com Arabi et al [39] Brunkhorst et al [38] Del La Rosa et al [42] Preiser et al [40] hypoglycaemic episode was associated with an increased risk of mortality (compared with those without an episode of severe hypoglycaemia). Egi et al [61] reported mild or moderate hypoglycaemia was associated with mortality in critically ill patients -with mortality substantially increasing according to severity of hypoglycaemia -and patients with diabetes were more likely to suffer from insulin-associated hypoglycaemia.
The blood glucose threshold that adverse events occur may be greater in patients with pre-existing diabetes. In a retrospective multi-centre observational study [32] increased mortality was reported in 12880 patients with pre-existing diabetes who had mean glucose concentrations between 4.4-6.2 mmol/L. While the investigators were not able to differentiate between patients with well-controlled or poorly-controlled diabetes, these data support the concept that the threshold for "hypoglycaemia" may be increased in critically ill patients with diabetes when compared to non diabetic patients. For example, if a patient typically has blood glucose concentrations above 10 mmol/L, and, in hospital, insulin is administered to achieve blood glucose concentration of about 6 mmol/L, this may result in a "relative" hypoglycaemia.
Glycaemic variability
Glycaemic variability (GV) describes the fluctuations in blood glucose concentrations, as marked fluctuations may be associated with multiple adverse effects such as apoptosis, cytokine production and increased markers of oxidative stress [59] . Oxidative stress markers have been shown to increase with glucose fluctuations [62, 63] . GV may be assessed by a number of methods. Techniques to quantify variability are reviewed elsewhere [64] . Multiple studies in the critically ill have established as an association with poor outcomes and GV [44, [65] [66] [67] [68] [69] [70] [71] , however the evidence in patients with pre-existing diabetes is limited and inconsistent (Table 8 ). In 2006, Egi et al [65] published a retrospective, electronic database analysis of 7049 ICU patients in 4 centres around Australia, using standard deviation as a marker of glucose variability, and focusing on the association of blood glucose variability and mortality [65] . Both mean and standard deviation of blood glucose were independently associated with mortality. A retrospective, single center cohort study of patients admitted with sepsis reported that GV was also independently associated with increased mortality and importantly, that this was independent of hypoglycaemia and the presence of diabetes [66] . Another retrospective study of 3252 patients reported that increased GV was associated with mortality [67] and diabetes was associated with greater GV. A prospective, observational study of 42 patients used non-lineal dynamics to measure glycaemia in time series [69] . Patients underwent continuous glucose monitoring system measuring interstitial glucose concentrations every 5 min for 48 h. The authors reported greater variability was associated with increasing mortality, even in patients with diabetes. However, given the small cohort, these results must be treated with caution.
Other studies have reported no relationship between mortality and GV in patients with diabetes. A retrospective, observational study of 4084 critically ill patients (942 with known diabetes) [68] reported that GV was associated with mortality in patients without diabetes, but not in patients with diabetes. More 701 June 10, 2015|Volume 6|Issue 5| WJD|www.wjgnet.com [44] of 299 patients there was no association between GV and mortality in their entire cohort, however the group with diabetes (128 patients) had a lower rate of mortality despite having a higher GV. Additionally, a retrospective analysis of 2782 ICU patients, comparing different GV indices and mean glucose concentrations to predict mortality and ICU acquired infections [70] reported that while GV was associated with infections and mortality in patients without pre-existing diabetes, in those with diabetes GV was greater but was not associated with either mortality or infection. In summary, there is a strong relationship between GV and mortality in critically ill patients that has been confirmed in multiple studies. However, with respect to patients with diabetes, data are inconsistent. This may be due a number of factors, including small numbers studied resulting in lack of power, or that patients with chronic hyperglycaemia are protected somewhat by glycaemic excursions during acute illness. Research is warranted to further understand whether GV is harmful in patients with pre-existing diabetes.
RATIONALE FOR PERSONALISED THERAPY AND THAT THE HARM FROM EACH OF THESE DOMAINS MAY VARY ACCORDING TO PRE EXISTING PHYSIOLOGY
Diabetes is known to be associated with a large burden of illness in the outpatient setting and is associated with increased mortality [72] . Paradoxically, as discussed, multiple studies exist suggesting that acute hyperglycaema in critically ill patients without diabetes (i.e., patients with CIAH) is associated with increased mortality and morbidity when compared to those with known diabetes [73] . There is growing evidence that chronic hyperglycaemia may lead to cellular conditioning, and that in fact, may be protective against acute hyperglycaemia mediated damage during an episode critical illness [1] . These outcomes suggest that current target glucose levels in patients naïve to hyperglycaemia, or those suffering from CIAH, may be harmful to those with chronic hyperglycaemia or poorly controlled diabetes.
CONCLUSION
This review articulates the need for further research to be done to identify the ideal glucose targets in critically ill patient with pre-existing diabetes. Not only does hyperglycaemia occur frequently in this group, but, recent data suggests that targeted blood glucose concentrations may benefit from consideration of a patient's premorbid glucose state.
Our recommendations are to avoid treating patients with diabetes as a homogenous group. Treatment of the critically ill patient with type 2 diabetes should be personalised to their internal milieu. There is preliminary evidence suggesting that higher blood glucose concentrations (e.g., up to 14 mmol/L) in patients with uncontrolled type 2 diabetes may not be
702
June 10, 2015|Volume 6|Issue 5| WJD|www.wjgnet.com harmful. For this reason it may be safer to target blood glucose concentrations between 10-14 mmol/L in this group. However, definitive studies of critically ill patients with poorly controlled diabetes are required before this approach is incorporated into clinical practice. In contrast, in patients with CIAH, or those with well-controlled diabetes (HbA1c < 7.0), a more conservative target (6-10 mmol/L) is supported by considerable data.
Ref.
Year Study pts
Study point
Non diabetic patients
Diabetic patients
Overall message
Egi et al [65] 2006 7049 GV (measured by SD and %CV) vs mortality (hospital and ICU) Both mean and GV of blood glucose were significantly and independently associated with ICU and hospital mortality GV was a stronger predictor of ICU mortality than mean glucose concentration Inc mortality when comparing highest and lowest glucose SD
No other significant relation with blood glucose (SD and mean) and ICU/hospital mortality Logistic regression: DM associated with decrease OR for ICU mortality The mean ± SD of blood glucose: Survivors 1.7 ± 1.3 mmol/L vs Non survivors 2.3 ± 1.6 mmol/L (P < 0.001)
Post logistic regression analysis, both mean and SD of blood glucose were significantly associated with ICU and hospital
Ali et al [66] 2008 1246 GV vs hospital mortality in septic ICU patients GV is independently associated with hospital mortality in sepsis Mortality rise remained even after adjusting for a diagnosis of diabetes Higher observed mortality with increasing levels of variability Higher odds of hospital mortality with lower mean blood glucose + high GV or higher mean blood glucose + lower GV Krinsely [67] 2008 3252 GV vs mortality in ICU patients Inc GV conferred a strong independent risk of mortality Multivariable regression analysis demonstrated that diabetes had an independent positive correlation to SD Amount of GV had a significant effect on mortalitye.g., patients with mean blood glucose 3.9-5.5 mmol/L mortality: Lowest GV 6% while high GV 30%
Krinsely [68] 2009 4084 Impact of DM or its absence on GV as a risk factor for mortality 
